Crossmark

Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma

Crossref DOI link: https://doi.org/10.1186/s12944-024-02298-4

Published Online: 2024-10-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bi, Yanran

Ying, Xihui

Chen, Wanbin

Wu, Jiahao

Kong, Chunli

Hu, Weiming

Fang, Shiji

Yu, Junchao

Zhai, Mengqian

Jiang, Chengli

Chen, Minjiang

Shen, Lin

Ji, Jiansong

Tu, Jianfei
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-01
More Information

Article History

Received: 18 July 2024

Accepted: 13 September 2024

First Online: 1 October 2024

Declarations

:

: This study retrospectively collected data on patients with HCC or CCA treated at the Fifth Affiliated Hospital of Wenzhou Medical University between January 2020 and December 2023, including tumor and adjacent non-tumor tissue samples. All tissues were obtained through surgical resection, following standard procedures to ensure sufficient tissue for metabolomic sequencing analysis. The study protocol was approved by the ethics committees of all participating centers and performed according to the Declaration of Helsinki. Ethical approval was granted by the Ethics Committee of the Fifth Affiliated Hospital of Wenzhou Medical University, approval number CTR20210090. All patients provided written informed consent for the use of their data for research purposes. For further inquiries and requests for experimental information, please contact the corresponding author.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below